ArticleAnnals of surgical oncology2025
Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDAC: a systematic review and meta-analysis of RCTs.Therapeutic advances in medical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials of neoadjuvant therapy for resectable pancreatic cancer are being conducted worldwide. The present study aimed to evaluate the treatment effect of neoadjuvant chemoradiotherapy (NACRT) compared with that of neoadjuvant chemotherapy (NAC) for patients with resectable pancreatic cancer.
methodsPatients with resectable pancreatic cancer who underwent surgical resection following NACRT or NAC between December 2011 and March 2017 were included in this study. Clinicopathological factors were compared using propensity score-matched analyses.
resultsA total of 347 patients were included; 170 underwent NACRT, and 177 underwent NAC. In the propensity score-matched cohort, the posttreatment CA19-9 level was significantly lower in the NACRT group. Pathological lymph node metastasis was significantly less and pathological tumor response was better in the NACRT group. Median overall survival was comparable (56.3 months in NACRT group and 50.5 months in NAC group). Disease-free survival did not differ significantly, but local recurrence was significantly less in the NACRT group. In the whole cohort, multivariate analysis showed that portal vein resection, transfusion, residual cancer, and absence of adjuvant chemotherapy were independent factors associated with poor overall survival. Logistic regression analysis showed that NAC, combined portal vein resection, and margin-positive resection were risk factors for local recurrence.
conclusionsNeoadjuvant chemoradiotherapy showed a stronger local control effect than NAC for resectable pancreatic cancer, but overall survival and disease-free survival were not significantly different between treatment groups. The present study suggests that more effective systemic treatment, as well as local control, is crucial even in patients with resectable pancreatic cancer.
Identifiers
40849373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.